PGE1 and Other Prostaglandins in the Treatment of Intermittent Claudication: A Meta-analysis

Abstract

In intermittent claudication, pharmacologic drugs and invasive measures are indicated in patients who do not benefit from exercise training. To evaluate the therapeutic role of prostaglandins (PGs), especially of prostaglandin E₁ (PGE₁), for this indication, the author performed a meta-analysis of all published prospective, randomized, controlled clinical studies in which descriptive sample statistics of the pain-free walking distance (PFWD) and the maximum walking distance (MWD) were available. In total, 9 studies with PGE₁ and 4 studies with other PGs (beraprost, iloprost, AS-013) that met these selection criteria could be analyzed. In patients treated with PGE₁ (n=344), PFWD increased significantly (p<0.001) more (+107%) than in patients treated with other PGs (n=402; +42%) or placebo (n=470; +24%). Similar results were also found for the MWD. Side effects were significantly (p<0.001) fewer with PGE₁ therapy than with other PGs (14.0% vs 30.8% of patients). In conclusion, PGE₁ proved to be the most effective and best tolerated of the PGs evaluated.

Get full access to this article

View all access options for this article.

References

de la Haye R , Diehm C , Blume J , et al : Eine epidemiologische Untersuchung zur Einsetzbarkeit und zu den Grenzen der physikalischen Therapie/Bewegungstherapie bei der arteriellen Verschluşkrankheit im Stadium II nach Fontaine. VASA 38(suppl):5-40, 1992.

TASC Working Group : Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Int Angiol 19(1 suppl 1):I-XXIV, 1-304, 2000.

Belch JJF , Bell PRF , Creissen D , et al : Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 95:2298-2302, 1997.

Blume J : Klinische Wirksamkeit der intraarteriellen Infusionstherapie mit Prostaglandin E1 im Stadium IIb der arteriellen Verschluşkrankheit. Therapiewoche 37:4819-4823, 1987.

Böger RH , Bode-Böger SM , Thiele W , et al : Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 32:1336-1344, 1998.

Diehm C , Balzer K , Bisler H , et al : Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: Results of a multicenter placebo-controlled, double-blind trial. J Vasc Surg 25:537-544, 1997.

Diehm C , Kühn A , Strauss R , et al : Effects of regular physical training in a supervised class and additional intravenous prostaglandin E1 and naftidrofuryl infusion therapy in patients with intermittent claudication—a controlled study. VASA 28(suppl):26-30, 1989.

Hepp W , von Bary S , Corovic D , et al : Clinical efficacy of iv prostaglandin E1 and IV pentoxifylline in patients with arterial occlusive disease of Fontaine stage IIb: A multicenter, randomized, comparative study. Int J Angiol 5:32-37, 1996.

Lièvre M , Azoulay S , Lion L , et al : A dose-effect study of beraprost sodium in intermittent claudication. J Cardiovasc Pharmacol 27:788-793, 1996.

10.

Lièvre M , Morand S , Besse B , et al : Oral beraprost sodium, a prostaglandin I2 analogue, for intermittent claudication. A double-blind, randomized, multicenter controlled trial. Circulation 102:426-431, 2000.

11.

Mangiafico RA , Messina R , Attinà T , et al : Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life in patients with intermittent claudication. Angiology 51:441-449, 2000.

12.

Müller-Bühl U , Diehm C , Krais T , et al : Clinical effects of intravenous iloprost in patients with intermittent claudication. Eur J Clin Pharmacol 33:127-131, 1987.

13.

Rudofsky G: Intravenöse PGE₁-Infusionsbehandlung bei Patienten mit arterieller Verschluşkrankheit im Stadium IIb. In: Prostaglandin E₁—Wirkungen und therapeutische Wirksamkeit, ed. by Heidrich H, Böhme H, Rogatti W. Berlin: Springer Verlag, 1988, pp 103-111.

14.

Rudofsky G , Altenhoff B , Meyer P , et al : Intra-arterial perfusion with prostaglandin E1 in patients with intermittent claudication. VASA 17(suppl):47-51, 1987.

15.

Scheffler P , de la Hamette D , Gross J , et al : Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Circulation 90:818-822, 1994.

16.

Reiter M , Bucek RA , Stümpflen A , et al : Prostanoids in the treatment of intermittent claudication—a meta-analysis. VASA 31:219-224, 2002.

17.

Dean SM : Pharmacologic treatment for intermittent claudication. Vasc Med 7:301-309, 2002.

18.

Hiatt WR : Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344:1608-1621, 2001.

19.

Creutzig A , Bullinger M , Cachovan M , et al : Improvement in the quality of life after IV PGE1 therapy for intermittent claudication. VASA 26(suppl):122-127, 1997.

20.

Heidrich H , Breddin HK , Rudofsky G , et al : Cardiopulmonary effects and safety of prostaglandin E1: A review. Int J Angiol 3:160-168, 1994.